Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum β-lactamase-producing Enterobacteriaceae

Chin Te Lu, Yin Ching Chuang, Wu Sun, Yung Ching Liu, Yu Jen Cheng, Po Liang Lu, Chih Ming Chen, Gwo Jong Hsu, Tsrang Neng Jang, Chun Ming Lee, Ping Cherng Chiang, Zhi Yuan Shi, Lih Shinn Wang, Hsiang Chi Kung, Hsiu Chen Lin, Chun Hsing Liao, Jien Wei Liu, Cheng Hua Huang, Shih Ming Tsao, Po Ren Hsueh

研究成果: 雜誌貢獻文章同行評審

10 引文 斯高帕斯(Scopus)

摘要

Tigecycline In-vitro Surveillance in Taiwan (TIST), initiated in 2006, is a nationwide surveillance programme designed to monitor longitudinally the in-vitro activity of tigecycline against commonly encountered resistant bacteria. This study compared the in-vitro activity of tigecycline against clinical isolates of resistant Gram-negative bacteria determined by the broth microdilution and Etest methods. A total of 622 isolates were collected from patients treated at 20 teaching hospitals. Tigecycline had excellent in-vitro activity against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (N = 275) with MIC90 0.5 μg/mL and a 99.6% susceptibility rate, and also against ESBL-producing Klebsiella pneumoniae (N = 324) with MIC90 2 μg/mL and a 98.5% susceptibility rate. For ESBL-producing Proteus mirabilis (N = 15) the MIC90 was 4 μg/mL with a 73.3% susceptibility rate. For ESBL-producing Klebsiella oxytoca (N = 8) the MIC50 and MIC90 were 0.5 and 1 μg/mL, respectively, with a 100% susceptibility rate. Limited agreement (

原文英語
期刊International Journal of Antimicrobial Agents
32
發行號SUPPL. 3
DOIs
出版狀態已發佈 - 十一月 2008
對外發佈

ASJC Scopus subject areas

  • 微生物學(醫學)
  • 傳染性疾病
  • 藥學(醫學)

指紋

深入研究「Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum β-lactamase-producing Enterobacteriaceae」主題。共同形成了獨特的指紋。

引用此